NASDAQ:RVPH Reviva Pharmaceuticals Q1 2026 Earnings Report $0.51 +0.01 (+2.00%) As of 03:40 PM Eastern ProfileEarnings HistoryForecast Reviva Pharmaceuticals EPS ResultsActual EPS-$0.46Consensus EPS -$0.36Beat/MissMissed by -$0.11One Year Ago EPSN/AReviva Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AReviva Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateWednesday, May 13, 2026Conference Call Time4:00PM ETUpcoming EarningsReviva Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Reviva Pharmaceuticals Earnings HeadlinesReviva Pharmaceuticals op Lytham Partners: brilaroxazine vordertSeptember 29, 2026 | nl.investing.comReviva Pharmaceuticals alla conferenza Lytham Partners: avanza brilaroxazineSeptember 29, 2026 | it.investing.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 5 at 1:00 AM | Reagan Gold Group (Ad)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of "Hold" from AnalystsSeptember 28, 2026 | americanbankingnews.comReviva to Participate in the Lytham Partners Fall 2026 Investor ConferenceSeptember 22, 2026 | globenewswire.comRVPH: Patent Filed for New FormulationAugust 17, 2026 | finance.yahoo.comSee More Reviva Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email. Email Address About Reviva PharmaceuticalsReviva Pharmaceuticals (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s research is based on its proprietary drug-discovery platform, which is designed to identify medicines that act on multiple serotonin and dopamine receptors. Reviva’s lead product candidate is brilaroxazine, formerly known as RP5063. Brilaroxazine is an investigational multimodal serotonin-dopamine activity modulator being developed for schizophrenia and other neuropsychiatric and inflammatory conditions, including bipolar depression, major depressive disorder, and certain dementia-related psychoses. The company’s programs remain subject to clinical development and regulatory review. Founded in 2011, Reviva Pharmaceuticals is headquartered in Cupertino, California. Its development activities have included clinical studies conducted in the United States and internationally. The company was founded and is led by Laxminarayan Bhat, Ph.D., who serves as president and chief executive officer.View Reviva Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
